MOASC Honors Young Investigator, Advancing Oncology Research

MOASC Honors Young Investigator, Advancing Oncology Research

Dr. Peter Zang receives the 2025 Cary Presant, MD Young Investigator Award for his groundbreaking research on metastatic castrate-resistant prostate cancer, improving treatment strategies and patient outcomes.

Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis

Promising therapeutic results of the prostate-specific membrane antigen (PSMA) ligand have been shown when labelling with lutetium-177 (177Lu). We performed a systematic review and meta-analysis to assess the therapeutic response of 177Lu-PSMA in the treatment of metastatic castration-resistant prostate cancer (mCRPC). A systematic review was conducted using electronic databases up to December 2016. Two reviewers independently extracted data and…

MOASC Honors Young Investigator, Advancing Oncology Research - PressReach

Dr. Peter Zang receives the 2025 Cary Presant, MD Young Investigator Award for his groundbreaking research on metastatic castrate-resistant prostate cancer, improving treatment strategies and patient outcomes. NEWPORT BEACH, Calif., April 3, 2025 /PRNewswire/ — The Medical Oncology Association of Southern California (MOASC) presented the highly anticipated 2025 Cary Presant, MD Young Investigator Award to Dr. Peter Zang, MD, Fellow in Hematology…

Lübeck – Prostate cancer is the most common malignant disease in men worldwide. The international research project PROMOTE ("Prostate Cancer Omics Oriented Intervention") aims to further develop diagnostic procedures using molecular analyses and artificial intelligence (AI) to reduce the number of unnecessary biopsies. In addition...

PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer: an analysis of 22 trials

The aim of this study was to determine the correlation between PSA response rate (PSA RR) and overall survival (OS) and identify PSA RR as a potential surr

Dr Morris on the FDA's Expanded Approval of Lutetium Lu 177 Vipivotide Tetraxetan for PSMA+ mCRPC

Michael J. Morris, MD, discusses the FD expanded approval of lutetium Lu 177 vipivotide tetraxetan for the treatment of patients with PSMA-positive mCRPC.